Business Wire

Qraft Technologies Closes US$146 Million Investment from SoftBank Group Entering into a Strategic Partnership to Accelerate AI in the Asset Management Industry

Share

AI enabled fintech company Qraft Technologies, Inc. (“Qraft” or “the company”) today announced that it has closed a US$146 million investment from SoftBank Group Corp. (“SoftBank”), which includes primary growth capital and secondary capital that will be used to fund share purchases from investors. The proposed transaction is expected to accelerate Qraft’s ongoing expansions into the US and China, while the two parties will also embark upon strategic projects that aim to pursue the possibilities of developing AI-enabled public portfolio management systems for SoftBank.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005190/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Marcus Kim, Founder and CEO of Qraft Technologies (Photo: Business Wire)

Headquartered in Seoul, Qraft develops and operates deep learning-based algorithms that provide portfolio weight signals which can be alpha-generative. The company has demonstrated the performance of its proprietary AI engine throughout its NYSE-listed ETFs. Qraft also offers B2B AI solutions ranging from data processing, investment strategy discovery, order execution to investment analysis & reporting that create unique values for global asset managers.

“Qraft can revolutionize the way financial institutions manage public equity assets, by providing their own AI technologies that have been tested and proven in the US equity market,” said Kentaro Matsui, Managing Partner at SB Investment Advisers and former Managing Director at SoftBank Group Corp. “On the back of our extensive AI ecosystem, we are thrilled to partner up with Mr. Kim and the Qraft team and support their mission of disrupting the asset management industry globally.”

Qraft CEO Marcus Kim believes “there will be enormous synergy to be had with SoftBank, the leader in investing in disruptive startups, and public equities management powered by Qraft’s AI. This only marks the start of AI technology fundamentally changing the US $100 trillion asset management industry.”

Robert Nestor, former President of Direxion ETFs and Head of iShares Factor ETF business, who recently took charge of Qraft's US expansion as US CEO, commented, “Qraft’s AI capabilities are second to none in investment management, and it is ripe for disruption with AI’s rapidly evolving capabilities. SoftBank recognizes this with its investment, and together we plan to change asset management.”

To support these effects, Qraft plans to accelerate its global business by hiring top-talents and opening new offices across New York, San Francisco as well as Hong Kong.

About Qraft Technologies

Qraft Technologies, Inc. is on a mission to transform alpha delivery in asset management. From data processing to alpha research and trade signals, Qraft has a track record of developing innovative AI solutions that have been adopted by major financial institutions and turned into successful AI products and services, including one of the leading AI-driven equity ETF platforms and Korea's largest robo-advisor engine provider.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Bernardo Soriano
Gregory FCA for Qraft Technologies
Email: bernardo@gregoryfca.com
Phone: 914-656-3880

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye